DDInter603 DDInter1676
A butyrophenone with general properties similar to those of haloperidol. It is used in conjunction with an opioid analgesic such as fentanyl to maintain the patient in a calm state of neuroleptanalgesia with indifference to surroundings but still able to cooperate with the surgeon. It is also used as a premedicant, as an antiemetic, and for the control of agitation in acute psychoses. (From Martindale, The Extra Pharmacopoeia, 29th ed, p593)
Siponimod, also known as _Mayzent_, by Novartis, is a new drug formulated for the management of Multiple Sclerosis (MS). It was approved by the FDA on March 26, 2019 and by Health Canada on February 20, 2020. This drug is considered a _sphingosine-1-phosphate (S1P) receptor modulator_ and is thought to play a role in suppressing the central nervous system inflammation that is associated with MS [FDA label]. Multiple Sclerosis (MS) is an autoimmune disease of the central nervous system that is chronic and inflammatory, disrupting communication between the brain and other parts of the body. Most patients diagnosed with this illness experience their initial disease symptoms between the age of 20 to 40, often the most productive years of life. Symptoms may include but are not limited to fatigue, gait changes, bowel or bladder dysfunction, abnormal muscle twitching, vision disturbance, and depressing or mood swings. MS is one of the most common causes of neurological disability in young adults and is found to occur more frequently in women than in men.[A176474,L5792]
Droperidol {u} (Compound) resembles {v} (Compound) Haloperidol
Droperidol {u} (Compound) resembles {v} (Compound) Fluspirilene
Droperidol {u} (Compound) binds {v} (Gene) ADRA1A
Droperidol {u} (Compound) is included by {v} (Pharmacologic Class) Dopamine D2 Antagonists
Droperidol {u} (Compound) downregulates {v} (Gene) CHIC2
Droperidol {u} (Compound) causes {v} (Side Effect) Altered state of consciousness
Droperidol {u} may cause a minor interaction that can limit clinical effects when taken with {v} Metronidazole
Droperidol {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Dextromethorphan
Droperidol {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Aldesleukin
Droperidol {u} may lead to a major life threatening interaction when taken with {v} Naloxone
Droperidol (Compound) resembles Haloperidol (Compound)
Droperidol (Compound) resembles Fluspirilene (Compound)
Droperidol (Compound) binds ADRA1A (Gene)
Droperidol (Compound) is included by Dopamine D2 Antagonists (Pharmacologic Class)
Droperidol (Compound) downregulates CHIC2 (Gene)
Droperidol (Compound) causes Altered state of consciousness (Side Effect)
Droperidol may cause a minor interaction that can limit clinical effects when taken with Metronidazole
Droperidol may cause a moderate interaction that could exacerbate diseases when taken with Dextromethorphan
Droperidol may cause a moderate interaction that could exacerbate diseases when taken with Aldesleukin
Droperidol may lead to a major life threatening interaction when taken with Naloxone